Scholarlink

<p>This study aims to investigate the effects of ulinastatin on therapeutic outcomes and inflammatory markers in children with septic shock. This study selected 117 children with septic shock admitted to our hospital from April 2023 to April 2024. Among them, 7 children had comorbidities, 3 dropped out during the research process, 5 did not continue to participate in the study due to other reasons, and 4 explicitly refused to participate. After screening and excluding the above - mentioned cases, A total of 98 children were allotted to experimental group (ulinastatin combined with routine antishock therapy, <i>n</i> = 49) and control group (routine antishock therapy, <i>n</i> = 49) using stratified random method. The therapeutic effects and levels of inflammatory markers were assessed before and after treatment using a double antibody sandwich ELISA. The outcome was significantly better in the experimental group compared to controls (<i>P</i> &lt; 0.05). Prior to treatment, there were no significant differences in the levels of CD64, procalcitonin (PCT), C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), and serum α-hydroxybutyrate dehydrogenase between the two groups (all <i>P</i> &gt; 0.05). After 7 days of treatment, the experimental group exhibited significantly lower levels of CD64, PCT, C-reactive protein, NLR, and serum α-hydroxybutyrate dehydrogenase compared to the control group (all <i>P</i> &lt; 0.001). Ulinastatin enhances the therapeutic efficacy in children with septic shock by reducing levels of associated inflammatory markers and promoting recovery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of ulinastatin on therapeutic outcomes and inflammatory markers in pediatric septic shock patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月13日

查看全文
  • Shan Gao,
  • Siman Cheng,
  • Qunwei Zhang,
  • Zhizhong Cheng,
  • Le Chen,
  • Zhihong Ren,
  • Yufen Jiang,
  • Wanlong Yin,
  • Pan Du,
  • Shan Gao,
  • Kunlun Zhan,
  • Liu Dai,
  • Chengjiao Huang

摘要

This study aims to investigate the effects of ulinastatin on therapeutic outcomes and inflammatory markers in children with septic shock. This study selected 117 children with septic shock admitted to our hospital from April 2023 to April 2024. Among them, 7 children had comorbidities, 3 dropped out during the research process, 5 did not continue to participate in the study due to other reasons, and 4 explicitly refused to participate. After screening and excluding the above - mentioned cases, A total of 98 children were allotted to experimental group (ulinastatin combined with routine antishock therapy, n = 49) and control group (routine antishock therapy, n = 49) using stratified random method. The therapeutic effects and levels of inflammatory markers were assessed before and after treatment using a double antibody sandwich ELISA. The outcome was significantly better in the experimental group compared to controls (P < 0.05). Prior to treatment, there were no significant differences in the levels of CD64, procalcitonin (PCT), C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), and serum α-hydroxybutyrate dehydrogenase between the two groups (all P > 0.05). After 7 days of treatment, the experimental group exhibited significantly lower levels of CD64, PCT, C-reactive protein, NLR, and serum α-hydroxybutyrate dehydrogenase compared to the control group (all P < 0.001). Ulinastatin enhances the therapeutic efficacy in children with septic shock by reducing levels of associated inflammatory markers and promoting recovery.